Managing General Partner
Jamie co-leads Frazier’s Life Sciences team and has over 25 years of experience working with entrepreneurs to found and build successful therapeutics-focused companies.
Jamie is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 12 years as a General Partner, Jamie has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Alpine Immune Sciences, AnaptysBio, Aptinyx, Entasis Therapeutics, and Millendo Therapeutics (formerly Atterocor). He is also a board observer for Gristone Oncology.
Prior to joining Frazier, Jamie served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR.
Jamie received his M.D. and Ph.D. in Biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 and 2016, Jamie was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.
University of Michigan (B.S.)
Stanford University (M.D., Ph.D.)